Capital International holds 2.01M shares of Ascendis Pharma (ASND)

Rhea-AI Filing Summary

Ascendis Pharma ownership update: Capital International Investors reports beneficial ownership of 2,013,285 shares, representing 3.2% of common stock. The filing states 61,977,408 shares believed outstanding and shows sole voting power of 2,005,343 and sole dispositive power of 2,013,285.

Insights

Institutional Ownership Analyst

Large asset manager reports a modest passive stake in Ascendis Pharma.

Capital International Investors discloses beneficial ownership of 2,013,285 shares or 3.2% of the issuer's common stock, per the amendment. The position is reported under passive/13G treatment rather than an activist filing.

This holding size is under the 5% threshold and indicates passive, non-control ownership; subsequent filings would show changes if the stake crosses regulatory thresholds or the holder changes intent.

Key Figures

Beneficial ownership: 2,013,285 shares Percent of class: 3.2% Shares outstanding (basis): 61,977,408 shares +2 more

5 metrics

Beneficial ownership 2,013,285 shares reported beneficially owned

Percent of class 3.2% of common stock

Shares outstanding (basis) 61,977,408 shares shares believed to be outstanding

Sole voting power 2,005,343 shares sole power to vote

Sole dispositive power 2,013,285 shares sole power to dispose

Key Terms

Schedule 13G/A, Beneficial owner, Depository Receipts, Sole dispositive power

4 terms

Schedule 13G/A regulatory

"Amendment No. 1; beneficial ownership disclosure"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial owner financial

"CII is deemed to be the beneficial owner of 2,013,285 shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Depository Receipts financial

"Shares reported include 2,013,285 Depository Receipts"

A depository receipt is a tradable certificate issued by a bank that represents ownership of shares held in a foreign company, letting investors buy and sell those shares on their local stock market without dealing with the foreign exchange and custody details. Think of it as a local receipt for a piece of a foreign company kept in a secure vault abroad; it matters because it makes international investing easier, often increases liquidity, and can affect dividend payments and currency risk.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 2,013,285"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Ascendis Pharma AS

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04351P101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 04351P101

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,005,343.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,013,285.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,013,285.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ascendis Pharma AS
(b)	Address of issuer's principal executive offices: TUBORG BOULEVARD 12, HELLERUP, Denmark
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 04351P101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,013,285 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 2,013,285 shares or 3.2% of the 61,977,408 shares believed to be outstanding. Shares reported include 2,013,285 Depository Receipts, which represent 2,013,285 Common Stock.
(b)	Percent of class: 3.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,005,343
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,013,285
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Aaron Espin
Name/Title:	Senior Vice President
Date:	05/13/2026

FAQ

How many Ascendis Pharma (ASND) shares does Capital International Investors own?

Capital International Investors beneficially owns 2,013,285 shares, representing 3.2% of the class. This figure is reported in the Schedule 13G/A amendment and is based on 61,977,408 shares believed outstanding.

Does Capital International Investors have voting control over ASND shares?

The filing shows sole voting power for 2,005,343 shares and sole dispositive power for 2,013,285 shares. These line items indicate who can vote and who can direct disposition of the reported shares.

Is this a passive or activist filing for Ascendis Pharma?

This Schedule 13G/A amendment reflects a passive ownership disclosure rather than an activist 13D filing. The holder reports ownership under the investment management umbrella of Capital International Investors.

What percentage of Ascendis Pharma is represented by the reported stake?

The reported stake equals 3.2% of common stock. The filing ties that percentage to an outstanding share base of 61,977,408 shares believed outstanding used for the calculation.

Who signed the Schedule 13G/A amendment for Capital International Investors?

The filing is signed by Aaron Espin, identified as Senior Vice President, with the signature date of 05/13/2026 on the amendment document.